Search

Your search keyword '"OVERALL survival"' showing total 81 results
Start Over Descriptor "OVERALL survival" Publication Year Range Last 10 years Language english Publisher mjh life sciences
81 results on '"OVERALL survival"'

1. 18-Month Survival Results of Neoadjuvant Cemiplimab in Advanced Resectable CSCC May Lead to Reconsideration of Adjuvant Treatment.

Author

Joszt, Laura

Subjects
*DRUG efficacy, *IMMUNE checkpoint inhibitors, *CANCER relapse, *SKIN tumors, *COMBINED modality therapy, *SQUAMOUS cell carcinoma, *PREANESTHETIC medication, *OVERALL survival
Abstract

The article reports on the results of a phase 2 trial on the use of the neoadjuvant cemplimab in treating patients with resectable stage II to stage IV cutaneous squamous cell carcinoma (CSCC). According to Doctor Neil D. Gross of the University of Texas MD Anderson Cancer Center, the drug showed favorable survival results in patients with 51% of them showing pathologic complete response (pCR) rate per central review.

Published
2023

3. Impactful Studies Challenge the Status Quo at GI Conference.

Author

Berberabe, Tony

Subjects
GASTROINTESTINAL tumors, MEDICAL quality control, CLINICAL trials, CANCER patient medical care, ENDOTHELIAL growth factors, IMMUNOTHERAPY, CONFERENCES & conventions, COLORECTAL cancer, IMMUNE checkpoint inhibitors, PANCREATIC tumors, MONOCLONAL antibodies, DUCTAL carcinoma, DRUG efficacy, PROGRESSION-free survival, ONCOLOGISTS, HEALTH care teams, SEQUENCE analysis, OVERALL survival
Published
2024

4. Novel Approaches Focus on Limiting Toxicity in Older Patients with ALL.

Author

Berberabe, Tony

Subjects
THERAPEUTIC use of antineoplastic agents, THERAPEUTIC use of monoclonal antibodies, SURVIVAL rate, DISEASE remission, MONOCLONAL antibodies, LYMPHOBLASTIC leukemia, DISEASE relapse, PROGRESSION-free survival, TOXICITY testing, OVERALL survival, CHILDREN, OLD age
Published
2024

5. 2023 World Conference on Lung Cancer.

Subjects
LUNG cancer, PERIOPERATIVE care, GENETIC mutation, CANCER chemotherapy, CONFERENCES & conventions, LUNG tumors, MONOCLONAL antibodies, PLACEBOS, MEDICAL societies, OVERALL survival
Published
2023

6. 2023 ASCO Genitourinary Cancers Symposium Data at a Glance.

Subjects
GENITOURINARY organ tumors, CANCER chemotherapy, PAPILLARY carcinoma, CONFERENCES & conventions, CASTRATION-resistant prostate cancer, SURVIVAL analysis (Biometry), PROGRESSION-free survival, OVERALL survival
Published
2023

7. Expanding 177Lutetium-PSMA-617 Use in the Community.

Author

Kurian, Matthew, Gjyshi, Olsi, and Rawe, Jason

Subjects
THERAPEUTIC use of antineoplastic agents, CASTRATION-resistant prostate cancer, HEALTH services accessibility, CHEMICAL elements, CHEMORADIOTHERAPY, POSITRON emission tomography, METASTASIS, CANCER chemotherapy, PROSTATE-specific membrane antigen, QUALITY of life, DNA damage, PROGRESSION-free survival, DISEASE progression, OVERALL survival
Published
2024

8. The Benefits of Elacestrant in HR+/HER2– Metastatic Breast Cancer Subgroups.

Author

Kaklamani, Virginia G.

Subjects
LIVER disease diagnosis, BREAST cancer diagnosis, SENTINEL lymph node biopsy, DOCETAXEL, AROMATASE inhibitors, PROTEIN kinase inhibitors, HORMONE receptor positive breast cancer, PATIENT safety, COMPUTED tomography, CYSTS (Pathology), DECISION making in clinical medicine, METASTASIS, ESTROGEN receptors, ADJUVANT chemotherapy, DUCTAL carcinoma, ONCOGENES, NEEDLE biopsy, DRUG efficacy, QUALITY of life, GENETIC mutation, LUMPECTOMY, CYCLOPHOSPHAMIDE, OVERALL survival
Published
2024

9. Clinical Updates: KIDNEY CANCER. Updated data show OS benefit with adjuvant pembrolizumab in ccRCC.

Author

CLARKE, HANNAH and HOLLASCH, MEGAN

Subjects
*THERAPEUTIC use of monoclonal antibodies, *RISK assessment, *PLACEBOS, *DEATH, *CANCER relapse, *DRUG side effects, *PATIENT safety, *CLINICAL trials, *TERMINATION of treatment, *NEPHRECTOMY, *RENAL cell carcinoma, *DISEASE relapse, *PROGRESSION-free survival, *TUMOR classification, *OVERALL survival, *PATIENT aftercare, *EVALUATION, *DISEASE risk factors
Abstract

The article discusses updated data as of 2024 which shows that adjuvant pembrolizumab (Keytruda) extended overall survival (OS) in patients with clear cell renal cell carcinoma (ccRCC) at medium or high risk of recurrence. It states that the therapy improved disease-free survival (DFS) and lowered distant and local disease recurrence. Also noted are the occurrences of immune-mediated adverse events (AE) and infusion reactions among patients.

Published
2024

10. From the Co-Editor in Chief: BCG-unresponsive NMIBC: Advancements are moving the needle.

Author

Cookson, Michael S.

Subjects
*NON-muscle invasive bladder cancer, *GENE therapy, *UROLOGY, *BCG vaccines, *IMMUNOTHERAPY, *ANTINEOPLASTIC agents, *DISEASE management, *TREATMENT effectiveness, *SEVERITY of illness index, *IMMUNE checkpoint inhibitors, *OVERALL survival, BLADDER tumors
Abstract

The article highlights advancements in the treatment of Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC). These include nadofaragene firadenovec intravesical gene therapy, pembrolizumab systemic therapy, TAR-200 drug intravesical delivery system using gemcitabine and gemcitabine plus a PD-L1 inhibitor, combination chemotherapy with gemcitabine and docetaxel, and QUILT-3.032 study on the synergy between immune checkpoint inhibitors and targeted therapies.

Published
2024

12. Survival Outcomes and PROs Favor Cemiplimab + Chemotherapy vs Chemotherapy Alone in Advanced NSCLC Regardless of PD-L1 Status.

Author

Joszt, Laura

Subjects
*THERAPEUTIC use of monoclonal antibodies, *THERAPEUTIC use of antineoplastic agents, *LUNG cancer, *DISEASE progression, *EVALUATION of human services programs, *COMBINATION drug therapy, *EPIDERMAL growth factor receptors, *LUNG tumors, *CHEMORADIOTHERAPY, *MEDICAL care research, *TUMOR classification, *TREATMENT effectiveness, *CANCER patients, *ANAPLASTIC lymphoma kinase, *SURVIVAL analysis (Biometry), *QUALITY of life, *PROGRESSION-free survival, *IMMUNOTHERAPY, *PATIENT safety, *OVERALL survival, *CHEMICAL inhibitors
Abstract

The article reports on the results of the 3 EMPOWER-Lung 3 study that were presented at the 2023 European Society for Medical Oncology Congress, showing that cemiplimab plus chemotherapy showed better favorable survival benefits and patient-reported outcomes (PRO) in patients with advanced non-small cell lung cancer (NSCLC). Also cited are the median overall survival (OS), objective response rate (ORR), and progression-free survival (PFS) study results.

Published
2023

13. Induction Chemotherapy Prior to Chemoradiation Represents Potential New SOC in Locally Advanced Cervical Cancer.

Author

Ryan, Chris

Subjects
*THERAPEUTIC use of antineoplastic agents, *DISEASE progression, *CARBOPLATIN, *CHEMORADIOTHERAPY, *PROGRESSION-free survival, *PACLITAXEL, *INDUCTION chemotherapy, *OVERALL survival, CERVIX uteri tumors
Abstract

The article reports on the results of the phase 3 INTERLACE trial showing that induction chemotherapy followed by chemoradiation lowered by 35% the risk of disease progression or death as compared to chemoradiation alone in patients with locally advanced cervical cancer. According to lead study author Mary McCormack, induction chemotherapy with paclitaxel and carboplatin should be considered as a standard treatment.

Published
2023

14. Clinical Updates: PROSTATE CANCER. Darolutamide delays time to progression from mHSPC to mCRPC vs placebo.

Author

SAYLOR, BENJAMIN P.

Subjects
*THERAPEUTIC use of antineoplastic agents, *DOCETAXEL, *ANTIANDROGENS, *CASTRATION-resistant prostate cancer, *PLACEBOS, *PROSTATE tumors, *TREATMENT effectiveness, *METASTASIS, *DISEASE progression, *OVERALL survival
Abstract

The article focuses on the results of the phase three ARASENS trial on the effectiveness of darolutamide as a treatment in patients with metastatic hormone-sensitive prostate cancer, which were presented at the 2024 American Society of Clinical Oncology Annual Meeting held in Chicago, Illinois. Topics discussed include the improvementin the overall survival and delay time to progression to metastatic castration-resistant disease, and the definition of postprogression survival.

Published
2024

15. Clinical Updates: PROSTATE CANCER. Survival may be improving in de novo mHSPC, new data suggest.

Author

CLARKE, HANNAH

Subjects
*THERAPEUTIC use of antineoplastic agents, *PROSTATE tumors, *EVALUATION of medical care, *CANCER patients, *METASTASIS, *HORMONE therapy, *OVERALL survival, *TIME, *COMORBIDITY
Abstract

The article focuses on a study which shows an improvement in the overall survival (OS) among patients with de novo metastatic hormone-sensitive prostate cancer in clinical practice in the U.S. from 2000 to 2019, which references a research paper by Martin Schoen et al., published in an issue of the "JAMA Network Open." Topics discussed include the median OS in patients younger than 70 years, and the significant role of combination therapy in this improvement.

Published
2024

16. Clinical Updates: BLADDER CANCER. Adding durvalumab to chemotherapy extends survival in MIBC.

Author

CLARKE, HANNAH

Subjects
*PREVENTION of drug side effects, *THERAPEUTIC use of monoclonal antibodies, *CANCER relapse, *PATIENT safety, *INVESTIGATIONAL drugs, *TERMINATION of treatment, *CLINICAL trials, *CANCER chemotherapy, *METASTASIS, *DRUG approval, *ENDOMETRIAL tumors, *COMBINED modality therapy, *DRUG efficacy, *PROGRESSION-free survival, *LUNG cancer, *OVERALL survival, *DISEASE progression, *HEPATOCELLULAR carcinoma, TUMOR surgery, BLADDER tumors, BILE duct tumors
Abstract

The article focuses on a news release from AstraZeneca on the results of the phase three NIAGARA trial, which shows the effectiveness of the combination of durvalumab and chemotherapy in improving event-free survival and overall survival in patients with muscle-invasive bladder cancer. Topics discussed include the safety of durvalumab in the trial, and the selection of the participants.

Published
2024

17. Blue light cystoscopy decreases risk of recurrence, progression in NMIBC.

Author

CLARKE, HANNAH

Subjects
*NON-muscle invasive bladder cancer, *CYSTOSCOPY, *EARLY detection of cancer, *DISEASE relapse, *PROGRESSION-free survival, *DISEASE progression, *OVERALL survival
Abstract

The article discusses 2024 data which showed that blue light cystoscopy (BLC) is linked to improved outcomes in patients with non-muscle-invasive bladder cancer (NMIBC) compared to white light cystoscopy (WLC). Topics covered include the comparatively lower recurrence risk and progression risk for patients following BLC, and the latter's improved overall survival. Also noted is improved tumor visualization's help in determining intravesical therapy use, such as Bacillus Calmette-Guerin (BCG).

Published
2024

20. Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.

Author

Niazi, Muhammad Rafay Khan, Jahangir, Abdullah, Sahra, Syeda, Sattar, Saud Bin Abdul, Asti, Divya, and Bershadskiy, Alexander

Abstract

BACKGROUND: PARP inhibitors have been recently approved by the FDA for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Their effectiveness is seen when used with androgen deprivation therapy in patients with or without deleterious germline and somatic genetic mutations. OBJECTIVES: To identify all the randomized controlled trials (RCTs) in which PARP inhibitors have been assessed in the treatment of mCRPC, and to compare the efficacy of PARP inhibitors in these patients with standard-of-care (SOC)/antihormonal therapies like abiraterone acetate (Zytiga) or enzalutamide (Xtandi) in terms of progression-free survival (PFS) and overall survival (OS). SEARCH STRATEGY: A systemic review search was conducted using PubMed, Embase, and Central Cochrane Registry. SELECTION CRITERIA: Randomized clinical trials with PARP inhibitors, with or without antihormonal therapy, as the intervention arm, with SOC as control. DATA ANALYSIS: HRs were calculated for PFS and OS. For effect sizes, a confidence interval of 95% was used, and for statistical significance, a P value of less than .05 was used. Analysis was done using random and fixed effect analysis and both were reported. Heterogeneity was evaluated using I2 statistic. RESULTS: Three RCTs were included in the analysis. PARP inhibitors showed a statistically significant improvement in OS when calculated using a fixed model (HR, 0.751; 95% CI, 0.582-0.968) but the improvement was not significant when calculated using a random model (HR, 0.758; 95% CI, 0.565- 1.017; I2 = 23). Similarly, the improvement in PFS was statistically significant when calculated using a fixed model (HR, 0.626; 95% CI, 0.521-0.752), and no statistical significance was noted with a random model (HR, 0.674; 95% CI, 0.437-1.039; I2 = 80). CONCLUSIONS: PARP inhibitors contributed to significant increases in PFS and OS when used with or without antihormonal agents like abiraterone or enzalutamide. This efficacy was pronounced among the patients with deleterious germline or somatic homologous recombination repair gene mutations, although patients without these mutations also showed a better PFS and OS in comparison with SOC therapy. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

21. Paclitaxel/Ramucirumab Prolongs Survival in Gastric Cancer.

Author

Bayer, Morgan

Subjects
THERAPEUTIC use of antineoplastic agents, THERAPEUTIC use of antimetabolites, THERAPEUTIC use of monoclonal antibodies, PLATINUM compounds, STOMACH tumors, DRUG side effects, PATIENT safety, IMMUNOTHERAPY, TREATMENT effectiveness, CANCER chemotherapy, COMBINED modality therapy, DRUG efficacy, PACLITAXEL, PROGRESSION-free survival, OVERALL survival, BIOMARKERS, EVALUATION
Published
2024

23. Evaluating the Role of Neoadjuvant Sacituzumab Govitecan in Bladder Cancer.

Author

Inman, Silas

Subjects
THERAPEUTIC use of antineoplastic agents, BLADDER tumors, DRUG toxicity, PATIENT safety, DRUG side effects, ENZYME inhibitors, ANTINEOPLASTIC agents, TUMOR markers, GENETIC polymorphisms, DRUG approval, COMBINED modality therapy, QUALITY of life, OVERALL survival, PHARMACODYNAMICS
Published
2024

24. Unlocking Latest Insights Into HR-Positive, HER2-Negative Treatment Strategies.

Author

Bayer, Morgan

Subjects
BREAST cancer prognosis, THERAPEUTIC use of antineoplastic agents, PROTEIN kinase inhibitors, HORMONE receptor positive breast cancer, BREAST tumors, CELLULAR signal transduction, DECISION making, METASTASIS, ADJUVANT chemotherapy, HORMONE therapy, PROGRESSION-free survival, GENETIC mutation, OVERALL survival
Published
2024

25. Nogapendekin alfa inbakicept-pmln (N-803; Anktiva).

Subjects
NON-muscle invasive bladder cancer, COMBINATION drug therapy, BLADDER tumors, MYCOBACTERIUM, PATIENT safety, DRUG approval, DRUG efficacy, PROGRESSION-free survival, CELL receptors, CARCINOMA in situ, OVERALL survival, THERAPEUTICS
Published
2024

26. Linvoseltamab Delivers Deep, Durable Responses in R/R Multiple Myeloma.

Author

Rosa, Kristi

Subjects
THERAPEUTIC use of monoclonal antibodies, MULTIPLE myeloma, RISK assessment, SYNDROMES, PATIENT safety, DRUG side effects, NEUROTOXICOLOGY, DRUG administration, MONOCLONAL antibodies, DRUG efficacy, DISEASE relapse, PROGRESSION-free survival, PATIENT aftercare, OVERALL survival, EVALUATION, DISEASE risk factors
Published
2024

27. Amivantamab/Chemotherapy Prolongs Progression-Free Survival in NSCLC.

Author

Bayer, Morgan

Subjects
THERAPEUTIC use of antineoplastic agents, THERAPEUTIC use of monoclonal antibodies, COMBINATION drug therapy, PROTEIN-tyrosine kinase inhibitors, CONFERENCES & conventions, PATIENT care, CANCER chemotherapy, LUNG cancer, PROGRESSION-free survival, GENETIC mutation, EPIDERMAL growth factor receptors, DISEASE progression, OVERALL survival
Published
2024

29. Atara Submits BLA for Cell Therapy for Post-Transplant Complication.

Subjects
BIOTHERAPY, TRANSPLANTATION of organs, tissues, etc., MEETINGS, RITUXIMAB, BIOLOGICAL products, CANCER chemotherapy, DRUG approval, LYMPHOPROLIFERATIVE disorders, DRUG laws, OVERALL survival
Abstract

The article details Atara Biotherapeutics' submission of a biologics license application to the FDA for tabelecleucel (tab-cel) as a treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). Topics include the significant need for a targeted therapy for EBV+ PTLD, tab-cel's efficacy and safety data from clinical studies, and the financial and marketing arrangements between Atara and Pierre Fabre Laboratories.

Published
2024

30. FDA Grants Full Approval to Elahere.

Subjects
THERAPEUTIC use of antineoplastic agents, FOLIC acid metabolism, THERAPEUTIC use of monoclonal antibodies, WOMEN, COST effectiveness, ANTINEOPLASTIC agents, OVARIAN tumors, CANCER patients, EYE care, DRUG approval, PHARMACY information services, MONOCLONAL antibodies, DRUG monitoring, DRUG efficacy, FALLOPIAN tube diseases, OVARIAN epithelial cancer, PERITONEUM tumors, PROGRESSION-free survival, CELL receptors, OVERALL survival, DRUG labeling
Abstract

The article focuses on the U.S. Food and Drug Administration (FDA) has approved Elahere for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients with prior systemic treatment. It reports that the approval was based on data from the confirmatory phase 3 MIRASOL trial, showing a reduction in death and cancer progression risk. Elahere, developed by ImmunoGen and acquired by AbbVie, targets folate receptor alpha.

Published
2024

32. Prostate cancer treatment deintensification: When less is more.

Author

COOKSON, MICHAEL S.

Subjects
*PROSTATE tumors treatment, *DISEASE progression, *ANTIANDROGENS, *INDIVIDUALIZED medicine, *TREATMENT effectiveness, *RISK assessment, *ADVERSE health care events, *DISEASE management, *PROSTATE tumors, *OVERALL survival
Abstract

In the article, the author discusses updates in the treatment of patients with advanced and metastatic prostate cancer, particularly the clinical trials showing the efficacy of treatment deintensification in the proper clinical context. Other topics include the potential benefits of deintensification like reduction of treatment-related adverse events (TRAE) and the various deintensification methods like radiation therapy with omission of androgen deprivation therapy (ADT).

Published
2023

34. First-Line Durvalumab Improves PFS in Advanced Endometrial Cancer.

Author

Mauro, Gina

Subjects
THERAPEUTIC use of antineoplastic agents, THERAPEUTIC use of monoclonal antibodies, PATIENT safety, IMMUNOTHERAPY, CONFERENCES & conventions, TREATMENT duration, ENDOMETRIAL tumors, CANCER chemotherapy, PROGRESSION-free survival, OVERALL survival
Published
2024

39. Amivantamab-vmjw (Rybrevant).

Subjects
THERAPEUTIC use of antineoplastic agents, THERAPEUTIC use of monoclonal antibodies, PEMETREXED, CARBOPLATIN, DRUG approval, METASTASIS, MONOCLONAL antibodies, DRUG efficacy, LUNG cancer, GENETIC mutation, PROGRESSION-free survival, EPIDERMAL growth factor receptors, OVERALL survival
Published
2024

40. Ibrutinib, Venetoclax Trial Boosts PFS in MCL.

Author

Sava, Jordyn

Subjects
NON-Hodgkin's lymphoma, CANCER relapse, PATIENT safety, ANTINEOPLASTIC agents, PROTEIN-tyrosine kinase inhibitors, PROGRESSION-free survival, OVERALL survival, DRUG tolerance, PHARMACODYNAMICS
Published
2024

41. Lifileucel Shows Long-Term Efficacy in Melanoma.

Author

Flaherty, Courtney

Subjects
MELANOMA treatment, T cells, IMMUNOTHERAPY, CELLULAR therapy, CONFERENCES & conventions, ONCOLOGY, TREATMENT effectiveness, DESCRIPTIVE statistics, DRUG approval, DRUG efficacy, OVERALL survival, EVALUATION
Published
2024

42. Ongoing Data Support Frontline Triplet in NSCLC.

Author

Berberabe, Tony

Subjects
THERAPEUTIC use of antineoplastic agents, SURVIVAL rate, ANTINEOPLASTIC agents, CONFERENCES & conventions, DESCRIPTIVE statistics, TREATMENT duration, TREATMENT effectiveness, CANCER chemotherapy, LUNG cancer, GENETIC mutation, OVERALL survival
Published
2024

43. Trastuzumab Deruxtecan (T-Dxd; Enhertu).

Subjects
THERAPEUTIC use of monoclonal antibodies, TRASTUZUMAB, MEDICAL prescriptions, BREAST tumors, CONFERENCES & conventions, PROGRESSION-free survival, OVERALL survival
Published
2024

44. FDA Withdraws Approval of Pepaxto in Multiple Myeloma.

Author

Myshko, Denise

Subjects
THERAPEUTIC use of antineoplastic agents, DRUG approval, PRODUCT recall, DEXAMETHASONE, ANTINEOPLASTIC agents, MULTIPLE myeloma, OVERALL survival
Abstract

The article focuses on the U.S. Food and Drug Administration' (FDA) withdrawal of approval for Pepaxto in treating multiple myeloma due to the failure of its confirmatory study to demonstrate clinical benefit and safety. Topics discussed include the timeline of events leading to the withdrawal, the concerns raised by regulators regarding the drug's efficacy and safety, and Oncopeptides' response to the decision.

Published
2024

45. FDA Sets Date for First-in-Class Lung Cancer Therapy.

Subjects
THERAPEUTIC use of monoclonal antibodies, LUNG cancer, DISEASE progression, ANTI-inflammatory agents, LUNG tumors, METASTASIS, CANCER patients, QUALITY assurance, PROGRESSION-free survival, OVERALL survival, BREAST tumors, ADULTS
Abstract

The article focuses on the U.S. Food and Drug Administration's (FDA) approval of datopotamab deruxtecan (Dato-DXd) for treating non-small cell lung cancer (NSCLC), with an action date set for the fourth quarter of 2024. It reports that, if approved, it would be the first TROP2-directed antibody drug conjugate for NSCLC, a significant development considering lung cancer's high incidence and mortality rates.

Published
2024

46. FDA Approves Onivyde for First-line Metastatic Pancreatic Cancer.

Subjects
DRUG approval, PANCREATIC tumors, ADENOCARCINOMA, FOLINIC acid, COMBINATION drug therapy, IRINOTECAN, METASTASIS, CANCER patients, FLUOROURACIL, GEMCITABINE, PROGRESSION-free survival, OVERALL survival
Abstract

The article reports on the approval by the U.S. Food and Drug Administration (FDA) of Onivyde (irinotecan liposome) as a first-line treatment of adult patients with metastatic pancreatic adenocarcinoma. The drug is indicated to be used with the chemotherapy regimen of oxaliplatin, fluorouracil and leucovorin (NALIRIFOX). Also cited is the comment of Professor Zev Wainberg of the UCLA GI Oncology program on the drug.

Published
2024

47. FDA Sets Advisory Meeting for Abecma in Supplemental Multiple Myeloma Indication.

Subjects
MEETINGS, DISEASE progression, NEUROTOXICOLOGY, COMMITTEES, SYNDROMES, CYTOKINE release syndrome, MULTIPLE myeloma, PROGRESSION-free survival, OVERALL survival, DISEASE remission
Abstract

The article highlights Food and Drug Administration advisory meeting on March 15, 2024, to review Abecma's efficacy in earlier lines of treatment for relapsed or refractory multiple myeloma. Topics include the meeting's focus on overall survival data from the KarMMa-3 study, Abecma's performance in comparison to standard regimens, and its adverse event profile.

Published
2024

48. FDA Grants Full Approval of Balversa in Bladder Cancer.

Subjects
THERAPEUTIC use of antineoplastic agents, BLADDER tumors, DRUG approval, CANCER chemotherapy, METASTASIS, TUMOR classification, ENDOWMENTS, OVERALL survival, ADULTS
Abstract

The article reports on the drug approval granted by the U.S. Food and Drug Administration (FDA) to Johnson & Johnson's Balversa (erdafitinib) to treat patients with metastatic urothelial carcinoma. It informs the list price of Balversa for tablets and the copay program of prescription offered by Johnson & Johnson. An overview of the Cohort 1 of the open-label phase 3 THOR study on the overall survival of patients treated with Balversa compared with chemotherapy is provided.

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results